Details of activity:
|
Active against Mycobacterium tuberculosis, Mycobacterium smegmatis, and Mycobacterium abscessus
|
Propensity to select resistant mutants:
|
Yes, at ~1.6x10^-6 mutation frequency at 2x or 6xMIC
|
Description:
|
Synthetic small molecule identified from whole-cell screening of ~340,000 compounds of Molecular Libraries Small Molecular Repository; prodrug that requires deazaflavin-dependent reductase (Ddn) and possibly another F420-dependent reductase to be activated; orally bioavailable; reduces bacterial burden by 1.1 and 1.2 log CFU in chronic murine Mycobacterium tuberculosis infection model; analogues (i.e. HC2209 and HC2211) with similar antimicrobial profile reported
|
Institute where first reported:
|
Department of Microbiology and Molecular Genetics, Michigan State University, East Lansing, Michigan, USA
|
Year first mentioned:
|
2023
|
Development status:
|
Experimental
|